

Ms K Sanders
MRC - MEDICAL RESEARCH COUNCIL
CLINICAL TRIALS UNIT, 4TH FLOOR AVIATION HOUSE
125 KINGSWAY
LONDON
WC2B 6NH
UNITED KINGDOM

03/10/2011

Dear Ms K Sanders

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	00316/0225/001-0089
Eudract Number:	2004-000193-31
Product:	Celecoxib (Celebrex)
Protocol number:	PR08
Substantial Amendment Code Number:	PR08 V7.1 21 Jun 2011

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 05/09/2011.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**